Squamous Cell Lung Cancer Associated With Systemic Sclerosis

Kanaji, Nobuhiro; Okuda, Masaya; Dobashi, Hiroaki; Kameda, Tomohiro; Tadokoro, Akira; Wakiya, Risa; Kadowaki, Norimitsu; Bandoh, Shuji

doi:10.14740/jocmr2313w

Cited by 3 publications

(2 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The frequency of squamous cell carcinoma was higher in IPF than in non-ILD patients (35 vs. 13 %). In ILD patients, most tumors reportedly develop in the area affected by ILD (Fujimoto et al 2013 ; Kanaji et al 2015 ). The current study provides evidence that carcinogenesis in IPF differs from that in non-ILD patients in that it is not associated with EGFR mutation.…”

Section: Discussionmentioning

confidence: 99%

Impact of idiopathic pulmonary fibrosis on advanced non-small cell lung cancer survival

Kanaji

Tadokoro

Kita

et al. 2016

J Cancer Res Clin Oncol

Self Cite

View full text Add to dashboard Cite

Purpose The clinical features of patients with advanced non-small cell lung cancer (NSCLC) and interstitial lung disease (ILD) have not fully been elucidated. This study aimed to investigate the clinical features of these patients, particularly with idiopathic pulmonary fibrosis (IPF).Methods Data on 218 patients with pathologically confirmed diagnoses of NSCLC who had been treated with chemotherapy and/or molecular targeted therapy were retrospectively analyzed for progression-free survival (PFS), overall survival (OS), responses to first-line therapy, and incidence of acute exacerbations (AEs).ResultsFifty-three of the 218 patients were diagnosed with ILD, and 34 of them with IPF. The frequency of epidermal growth factor receptor (EGFR) mutation was significantly lower in ILD and IPF patients than in non-ILD patients (2 or 0 vs. 32 %, respectively). Median PFS and OS were significantly shorter in both ILD and IPF patients than in non-ILD patients (118, 92, and 196 days for PFS, and 267, 223, and 539 days for OS, respectively). Multivariate analysis showed that poor performance status, absence of EGFR mutation, and presence of IPF were poor prognostic factors for PFS and OS. Disease control rate (DCR) was significantly lower in ILD and IPF patients than in non-ILD patients regardless of the presence of EGFR mutation (67 or 53 vs. 85 %, respectively). The incidence of AEs of ILD was significantly higher during chemotherapy with docetaxel-containing regimens (seven of 38; 18.4 %).ConclusionsBoth IPF and ILD were associated with lower EGFR positivity, lower DCR, and shorter PFS and OS in advanced NSCLC patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Impact of idiopathic pulmonary fibrosis on advanced non-small cell lung cancer survival

Kanaji

Tadokoro

Kita

et al. 2016

J Cancer Res Clin Oncol

Self Cite

View full text Add to dashboard Cite

show abstract

“…There are sclerodactyly (Figure 3b) and also skin tightening of bilateral lower limbs (Figure 3c). lung, ovarian, oral cavity, and pharynx cancer, non-Hodgkin lymphoma, and colorectal cancer [11][12][13][14][15][16]. In this case series, we present two cases of paraneoplastic systemic sclerosis associated with adenocarcinoma of the lung and acute myeloid leukemia, highlighting the importance of considering an underlying malignancy in patients presenting with sclerodermic clinical features.…”

Section: Patient No2mentioning

confidence: 88%

Systemic Sclerosis and Malignancy: Unravelling the Link through a Paraneoplastic Systemic Sclerosis Case Series

Shan Kai,

Seow Lin,

Guo Ruey

et al. 2023

J Rheum Dis Treat

View full text Add to dashboard Cite

Check for updatesThis case series reports two cases of paraneoplastic rheumatic syndrome of systemic sclerosis presentation and underscores the importance of early recognition and treatment of the underlying malignancy for the successful management of these conditions. To identify and manage paraneoplastic syndromes, it is critical that rheumatologists, oncologists, and primary care practitioners collaborate effectively. Case Presentation Patient No.1The patient was a 63-year-old woman of Asian descent who was a non-smoker and non-alcoholic with underlying diabetes mellitus, hypertension, dyslipidemia, and hyperthyroidism. She worked as a chef and was on chronic prescriptions of the following medications: metformin 1g twice daily, biphasic insulin subcutaneous injection 20 units in the morning, then 14 units in the evening, perindopril 8 mg once daily, simvastatin 40 mg once daily and carbimazole 5 mg once daily. Her family history was notable for lymphoma and hepatocellular carcinoma among her first-degree relatives. She presented with a 3-month history of bilateral symmetrical polyarthritis involving small

show abstract

Peripheral-type small cell lung cancer is associated with better survival and higher frequency of interstitial lung disease

et al. 2017

View full text Add to dashboard Cite

Squamous Cell Lung Cancer Associated With Systemic Sclerosis

Cited by 3 publications

References 41 publications

Impact of idiopathic pulmonary fibrosis on advanced non-small cell lung cancer survival

Impact of idiopathic pulmonary fibrosis on advanced non-small cell lung cancer survival

Systemic Sclerosis and Malignancy: Unravelling the Link through a Paraneoplastic Systemic Sclerosis Case Series

Peripheral-type small cell lung cancer is associated with better survival and higher frequency of interstitial lung disease

Contact Info

Product

Resources

About